Marker Therapeutics Inc (MRKR): JACKSONVILLE, Florida, April 7, 2016 /PR...

Send PM Follow Ignore

Followers	3
Posts	217
Boards Moderated	0
Alias Born	10/16/2010

LaJollaCA

Re: None

Thursday, 04/07/2016 8:41:29 AM

Thursday, April 07, 2016 8:41:29 AM

JACKSONVILLE, Florida, April 7, 2016 /PRNewswire/ --

Doses for use at Mayo Clinic and other clinical sites
Stable, easily reconstituted product contains five folate receptor alpha peptides in a single vial
TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, announced today it has successfully completed formulation development, scale-up, GMP (Good Manufacturing Practice) manufacturing, and the release of TPIV 200, its multi-epitope folate receptor peptide vaccine for breast and ovarian cancer. The manufactured product contains five peptide antigens freeze dried in a single vial, ready for injection after reconstitution and addition of granulocyte-macrophage colony-stimulating factor (GM-CSF). TPIV 200 doses are now available for the upcoming Phase II clinical trials in both triple negative breast cancer and ovarian cancer.

http://finance.yahoo.com/news/tapimmune-completes-gmp-manufacturing-release-123000699.html